Retrospective Study
Copyright ©The Author(s) 2016.
World J Gastroenterol. Jul 14, 2016; 22(26): 6065-6075
Published online Jul 14, 2016. doi: 10.3748/wjg.v22.i26.6065
Figure 1
Figure 1 Patient flow. Ninety-six out of the 693 patients screened were found to be eligible. HPB: Hepato-pancreato-biliary cancer; Jan: January; Pts: Patients.
Figure 2
Figure 2 Graphical representation of each of the patient’s follow-up included in this study, time on chemotherapy, and time of radiological progression and development of a stent-related event.
Figure 3
Figure 3 Kaplan Meier graphic. Overall survival and type of stent-related event (SRE)-related consequence [mild (none/chemotherapy delayed) vs severe (chemotherapy interrupted/death)].